JAMA子刊:替格瑞洛联合“神药”阿司匹林在中度卒中患者治疗中是否效果更佳

2021-07-24 MedSci原创 MedSci原创

双重抗血小板治疗(DAPT)是早期处理轻度非心肌梗塞性缺血性卒中和短暂性缺血发作(TIA)的关键策略。

双重抗血小板治疗(DAPT)是早期处理轻度非心肌梗塞性缺血性卒中和短暂性缺血发作(TIA)的关键策略。氯吡格雷和阿司匹林的DAPT疗效和安全性已经在TIA或急性缺血性卒中的患者群体中进行了评估,CHANCE试验和POINT试验中均对高危患者进行了评估。

基于这些研究,目前的指南推荐对NIHSS评分在3分或以下的高危TIA和轻微非心源性缺血性卒中患者进行早期、短期(21天)的氯吡格雷和阿司匹林联合治疗。

在THALES试验中,对NIHSS评分为5分或以下的TIA或急性缺血性中风患者进行了替格瑞洛和阿司匹林的DAPT评估,其中约30%的患者在随机时NIHSS评分为4或5分。THALES试验表明,与单独使用阿司匹林相比,使用DAPT可降低30天内的中风或死亡风险,且严重的出血事件并不会增加。

然而, NIHSS基线评分为4至5分的中风患者与NIHSS评分为0至3分的患者对DAPT的反应可能不同,因为他们的神经系统损伤更严重,缺血损伤面积更大。例如,他们的脑出血风险更大。

鉴于以前没有随机试验评估DAPT在中度卒中(NIHSS评分为4至5分)患者中的疗效和安全性,DAPT的益处是否能扩展到NIHSS评分为4至5分的严重缺血性卒中患者,引起了卒中神经学家的兴趣。

THALES试验是一项随机试验,于2018年1月-2019年12月在28个国家的414家医院进行。这项探索性分析比较了中度中风患者(基线NIHSS评分为4至5分)与较轻度中风患者(NIHSS评分为0至3分)。共有9983名中风患者被纳入本分析。

症状发生后24小时内服用替格瑞洛(第1天180mg负荷剂量,第2至30天90mg,每天两次)或安慰剂。所有患者在第1天接受阿司匹林300至325mg,然后在第2至30天接受阿司匹林75至100mg。对患者再进行30天的观察。主要结果是30天内发生中风或死亡的时间。主要的安全结果是出现严重出血的时间。

总共有3312名患者出现了中度中风,6671名患者出现了轻度中风。在中度卒中组中,1293人(39.0%)为女性,平均(SD)年龄为64.5(10.8)岁;在轻度卒中组中,2518人(37.7%)为女性,平均(SD)年龄为64.8(11.2)岁。

在中度卒中患者中,替格瑞洛组主要结果事件率为7.6%(1671例中的129例),而安慰剂组为9.1%(1641例中的150例),差异无统计学意义(HR=0.84;95%CI,0.66-1.06)。在轻度中风患者中,替卡格雷组的主要结果事件率为4.7%,而安慰剂组为5.7%(3312人中的190人),同样无差异(HR=0.82;95%CI,0.66-1.01)。

但在中度卒中患者中,替格瑞洛组有8名患者(0.5%)和安慰剂组有4名患者(0.2%)发生严重出血,而在较轻的卒中患者中,分别有16名患者(0.5%)和3名患者(0.1%)发生严重出血。

在这项研究中,与不太严重的缺血性中风患者相比,中度缺血性中风患者替格瑞洛加阿司匹林与单用阿司匹林中获益一致。

 

参考文献:

Efficacy and Safety of Ticagrelor and Aspirin in Patients With Moderate Ischemic Stroke: An Exploratory Analysis of the THALES Randomized Clinical Trial. JAMA Neurol. Published online July 09, 2021. doi:10.1001/jamaneurol.2021.2440

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1720403, encodeId=66b21e2040356, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Sun Jun 19 10:21:37 CST 2022, time=2022-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006810, encodeId=4c8a100681095, content=学到了👌, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210121/3066131e88ca4c31a238db2bedac2f10/1d8e8a6a6c4c4256b2b4a24b6723d68a.jpg, createdBy=91092531490, createdName=滚滚兔🐰, createdTime=Tue Aug 10 23:55:38 CST 2021, time=2021-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002363, encodeId=da30100236300, content=非常受用, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210724/725901dc0ed249ebba9d096aacddde3f/a89b874e17434adb82b0c2dff5f374f1.jpg, createdBy=c0225555986, createdName=@gxl, createdTime=Sat Jul 24 19:23:23 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002230, encodeId=77b81002230ff, content=所以现在临床使用上面两个药相对安全吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210923/798b9a11e1834c52b6667d71ec29a2fe/c4404e92055a461b85f5cf0c06bb8497.jpg, createdBy=06ab5182837, createdName=146fe014m90暂无昵称, createdTime=Sat Jul 24 15:09:02 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026921, encodeId=299710269210c, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Sat Jul 24 14:21:37 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036762, encodeId=9f361036e62ed, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Sat Jul 24 14:21:37 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047402, encodeId=bdc8104e402ce, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Jul 24 14:21:37 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002207, encodeId=2f98100220ee6, content=学到了<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e3a5478833, createdName=ms5000000790714074, createdTime=Sat Jul 24 12:57:38 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002199, encodeId=ef42100219917, content=我想问的是能否替代氯吡格雷。, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c172830082, createdName=18327b53a6m, createdTime=Sat Jul 24 11:52:33 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002193, encodeId=949710021936c, content=又是阿司匹林, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210616/0f0e195fe7b24d569a1f39751df92fe2/ae01b1208252480f9e001617ce565271.jpg, createdBy=91e25526337, createdName=土豆你个马铃薯, createdTime=Sat Jul 24 11:23:00 CST 2021, time=2021-07-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1720403, encodeId=66b21e2040356, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Sun Jun 19 10:21:37 CST 2022, time=2022-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006810, encodeId=4c8a100681095, content=学到了👌, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210121/3066131e88ca4c31a238db2bedac2f10/1d8e8a6a6c4c4256b2b4a24b6723d68a.jpg, createdBy=91092531490, createdName=滚滚兔🐰, createdTime=Tue Aug 10 23:55:38 CST 2021, time=2021-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002363, encodeId=da30100236300, content=非常受用, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210724/725901dc0ed249ebba9d096aacddde3f/a89b874e17434adb82b0c2dff5f374f1.jpg, createdBy=c0225555986, createdName=@gxl, createdTime=Sat Jul 24 19:23:23 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002230, encodeId=77b81002230ff, content=所以现在临床使用上面两个药相对安全吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210923/798b9a11e1834c52b6667d71ec29a2fe/c4404e92055a461b85f5cf0c06bb8497.jpg, createdBy=06ab5182837, createdName=146fe014m90暂无昵称, createdTime=Sat Jul 24 15:09:02 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026921, encodeId=299710269210c, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Sat Jul 24 14:21:37 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036762, encodeId=9f361036e62ed, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Sat Jul 24 14:21:37 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047402, encodeId=bdc8104e402ce, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Jul 24 14:21:37 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002207, encodeId=2f98100220ee6, content=学到了<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e3a5478833, createdName=ms5000000790714074, createdTime=Sat Jul 24 12:57:38 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002199, encodeId=ef42100219917, content=我想问的是能否替代氯吡格雷。, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c172830082, createdName=18327b53a6m, createdTime=Sat Jul 24 11:52:33 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002193, encodeId=949710021936c, content=又是阿司匹林, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210616/0f0e195fe7b24d569a1f39751df92fe2/ae01b1208252480f9e001617ce565271.jpg, createdBy=91e25526337, createdName=土豆你个马铃薯, createdTime=Sat Jul 24 11:23:00 CST 2021, time=2021-07-24, status=1, ipAttribution=)]
    2021-08-10 滚滚兔🐰

    学到了👌

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1720403, encodeId=66b21e2040356, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Sun Jun 19 10:21:37 CST 2022, time=2022-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006810, encodeId=4c8a100681095, content=学到了👌, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210121/3066131e88ca4c31a238db2bedac2f10/1d8e8a6a6c4c4256b2b4a24b6723d68a.jpg, createdBy=91092531490, createdName=滚滚兔🐰, createdTime=Tue Aug 10 23:55:38 CST 2021, time=2021-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002363, encodeId=da30100236300, content=非常受用, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210724/725901dc0ed249ebba9d096aacddde3f/a89b874e17434adb82b0c2dff5f374f1.jpg, createdBy=c0225555986, createdName=@gxl, createdTime=Sat Jul 24 19:23:23 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002230, encodeId=77b81002230ff, content=所以现在临床使用上面两个药相对安全吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210923/798b9a11e1834c52b6667d71ec29a2fe/c4404e92055a461b85f5cf0c06bb8497.jpg, createdBy=06ab5182837, createdName=146fe014m90暂无昵称, createdTime=Sat Jul 24 15:09:02 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026921, encodeId=299710269210c, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Sat Jul 24 14:21:37 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036762, encodeId=9f361036e62ed, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Sat Jul 24 14:21:37 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047402, encodeId=bdc8104e402ce, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Jul 24 14:21:37 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002207, encodeId=2f98100220ee6, content=学到了<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e3a5478833, createdName=ms5000000790714074, createdTime=Sat Jul 24 12:57:38 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002199, encodeId=ef42100219917, content=我想问的是能否替代氯吡格雷。, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c172830082, createdName=18327b53a6m, createdTime=Sat Jul 24 11:52:33 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002193, encodeId=949710021936c, content=又是阿司匹林, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210616/0f0e195fe7b24d569a1f39751df92fe2/ae01b1208252480f9e001617ce565271.jpg, createdBy=91e25526337, createdName=土豆你个马铃薯, createdTime=Sat Jul 24 11:23:00 CST 2021, time=2021-07-24, status=1, ipAttribution=)]
    2021-07-24 @gxl

    非常受用

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1720403, encodeId=66b21e2040356, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Sun Jun 19 10:21:37 CST 2022, time=2022-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006810, encodeId=4c8a100681095, content=学到了👌, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210121/3066131e88ca4c31a238db2bedac2f10/1d8e8a6a6c4c4256b2b4a24b6723d68a.jpg, createdBy=91092531490, createdName=滚滚兔🐰, createdTime=Tue Aug 10 23:55:38 CST 2021, time=2021-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002363, encodeId=da30100236300, content=非常受用, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210724/725901dc0ed249ebba9d096aacddde3f/a89b874e17434adb82b0c2dff5f374f1.jpg, createdBy=c0225555986, createdName=@gxl, createdTime=Sat Jul 24 19:23:23 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002230, encodeId=77b81002230ff, content=所以现在临床使用上面两个药相对安全吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210923/798b9a11e1834c52b6667d71ec29a2fe/c4404e92055a461b85f5cf0c06bb8497.jpg, createdBy=06ab5182837, createdName=146fe014m90暂无昵称, createdTime=Sat Jul 24 15:09:02 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026921, encodeId=299710269210c, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Sat Jul 24 14:21:37 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036762, encodeId=9f361036e62ed, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Sat Jul 24 14:21:37 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047402, encodeId=bdc8104e402ce, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Jul 24 14:21:37 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002207, encodeId=2f98100220ee6, content=学到了<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e3a5478833, createdName=ms5000000790714074, createdTime=Sat Jul 24 12:57:38 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002199, encodeId=ef42100219917, content=我想问的是能否替代氯吡格雷。, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c172830082, createdName=18327b53a6m, createdTime=Sat Jul 24 11:52:33 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002193, encodeId=949710021936c, content=又是阿司匹林, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210616/0f0e195fe7b24d569a1f39751df92fe2/ae01b1208252480f9e001617ce565271.jpg, createdBy=91e25526337, createdName=土豆你个马铃薯, createdTime=Sat Jul 24 11:23:00 CST 2021, time=2021-07-24, status=1, ipAttribution=)]
    2021-07-24 146fe014m90暂无昵称

    所以现在临床使用上面两个药相对安全吗

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1720403, encodeId=66b21e2040356, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Sun Jun 19 10:21:37 CST 2022, time=2022-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006810, encodeId=4c8a100681095, content=学到了👌, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210121/3066131e88ca4c31a238db2bedac2f10/1d8e8a6a6c4c4256b2b4a24b6723d68a.jpg, createdBy=91092531490, createdName=滚滚兔🐰, createdTime=Tue Aug 10 23:55:38 CST 2021, time=2021-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002363, encodeId=da30100236300, content=非常受用, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210724/725901dc0ed249ebba9d096aacddde3f/a89b874e17434adb82b0c2dff5f374f1.jpg, createdBy=c0225555986, createdName=@gxl, createdTime=Sat Jul 24 19:23:23 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002230, encodeId=77b81002230ff, content=所以现在临床使用上面两个药相对安全吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210923/798b9a11e1834c52b6667d71ec29a2fe/c4404e92055a461b85f5cf0c06bb8497.jpg, createdBy=06ab5182837, createdName=146fe014m90暂无昵称, createdTime=Sat Jul 24 15:09:02 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026921, encodeId=299710269210c, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Sat Jul 24 14:21:37 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036762, encodeId=9f361036e62ed, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Sat Jul 24 14:21:37 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047402, encodeId=bdc8104e402ce, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Jul 24 14:21:37 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002207, encodeId=2f98100220ee6, content=学到了<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e3a5478833, createdName=ms5000000790714074, createdTime=Sat Jul 24 12:57:38 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002199, encodeId=ef42100219917, content=我想问的是能否替代氯吡格雷。, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c172830082, createdName=18327b53a6m, createdTime=Sat Jul 24 11:52:33 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002193, encodeId=949710021936c, content=又是阿司匹林, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210616/0f0e195fe7b24d569a1f39751df92fe2/ae01b1208252480f9e001617ce565271.jpg, createdBy=91e25526337, createdName=土豆你个马铃薯, createdTime=Sat Jul 24 11:23:00 CST 2021, time=2021-07-24, status=1, ipAttribution=)]
    2021-07-24 健健

    卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1720403, encodeId=66b21e2040356, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Sun Jun 19 10:21:37 CST 2022, time=2022-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006810, encodeId=4c8a100681095, content=学到了👌, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210121/3066131e88ca4c31a238db2bedac2f10/1d8e8a6a6c4c4256b2b4a24b6723d68a.jpg, createdBy=91092531490, createdName=滚滚兔🐰, createdTime=Tue Aug 10 23:55:38 CST 2021, time=2021-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002363, encodeId=da30100236300, content=非常受用, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210724/725901dc0ed249ebba9d096aacddde3f/a89b874e17434adb82b0c2dff5f374f1.jpg, createdBy=c0225555986, createdName=@gxl, createdTime=Sat Jul 24 19:23:23 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002230, encodeId=77b81002230ff, content=所以现在临床使用上面两个药相对安全吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210923/798b9a11e1834c52b6667d71ec29a2fe/c4404e92055a461b85f5cf0c06bb8497.jpg, createdBy=06ab5182837, createdName=146fe014m90暂无昵称, createdTime=Sat Jul 24 15:09:02 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026921, encodeId=299710269210c, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Sat Jul 24 14:21:37 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036762, encodeId=9f361036e62ed, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Sat Jul 24 14:21:37 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047402, encodeId=bdc8104e402ce, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Jul 24 14:21:37 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002207, encodeId=2f98100220ee6, content=学到了<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e3a5478833, createdName=ms5000000790714074, createdTime=Sat Jul 24 12:57:38 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002199, encodeId=ef42100219917, content=我想问的是能否替代氯吡格雷。, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c172830082, createdName=18327b53a6m, createdTime=Sat Jul 24 11:52:33 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002193, encodeId=949710021936c, content=又是阿司匹林, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210616/0f0e195fe7b24d569a1f39751df92fe2/ae01b1208252480f9e001617ce565271.jpg, createdBy=91e25526337, createdName=土豆你个马铃薯, createdTime=Sat Jul 24 11:23:00 CST 2021, time=2021-07-24, status=1, ipAttribution=)]
    2021-07-24 旺医

    顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1720403, encodeId=66b21e2040356, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Sun Jun 19 10:21:37 CST 2022, time=2022-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006810, encodeId=4c8a100681095, content=学到了👌, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210121/3066131e88ca4c31a238db2bedac2f10/1d8e8a6a6c4c4256b2b4a24b6723d68a.jpg, createdBy=91092531490, createdName=滚滚兔🐰, createdTime=Tue Aug 10 23:55:38 CST 2021, time=2021-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002363, encodeId=da30100236300, content=非常受用, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210724/725901dc0ed249ebba9d096aacddde3f/a89b874e17434adb82b0c2dff5f374f1.jpg, createdBy=c0225555986, createdName=@gxl, createdTime=Sat Jul 24 19:23:23 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002230, encodeId=77b81002230ff, content=所以现在临床使用上面两个药相对安全吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210923/798b9a11e1834c52b6667d71ec29a2fe/c4404e92055a461b85f5cf0c06bb8497.jpg, createdBy=06ab5182837, createdName=146fe014m90暂无昵称, createdTime=Sat Jul 24 15:09:02 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026921, encodeId=299710269210c, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Sat Jul 24 14:21:37 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036762, encodeId=9f361036e62ed, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Sat Jul 24 14:21:37 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047402, encodeId=bdc8104e402ce, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Jul 24 14:21:37 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002207, encodeId=2f98100220ee6, content=学到了<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e3a5478833, createdName=ms5000000790714074, createdTime=Sat Jul 24 12:57:38 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002199, encodeId=ef42100219917, content=我想问的是能否替代氯吡格雷。, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c172830082, createdName=18327b53a6m, createdTime=Sat Jul 24 11:52:33 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002193, encodeId=949710021936c, content=又是阿司匹林, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210616/0f0e195fe7b24d569a1f39751df92fe2/ae01b1208252480f9e001617ce565271.jpg, createdBy=91e25526337, createdName=土豆你个马铃薯, createdTime=Sat Jul 24 11:23:00 CST 2021, time=2021-07-24, status=1, ipAttribution=)]
    2021-07-24 CHANGE

    疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1720403, encodeId=66b21e2040356, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Sun Jun 19 10:21:37 CST 2022, time=2022-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006810, encodeId=4c8a100681095, content=学到了👌, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210121/3066131e88ca4c31a238db2bedac2f10/1d8e8a6a6c4c4256b2b4a24b6723d68a.jpg, createdBy=91092531490, createdName=滚滚兔🐰, createdTime=Tue Aug 10 23:55:38 CST 2021, time=2021-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002363, encodeId=da30100236300, content=非常受用, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210724/725901dc0ed249ebba9d096aacddde3f/a89b874e17434adb82b0c2dff5f374f1.jpg, createdBy=c0225555986, createdName=@gxl, createdTime=Sat Jul 24 19:23:23 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002230, encodeId=77b81002230ff, content=所以现在临床使用上面两个药相对安全吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210923/798b9a11e1834c52b6667d71ec29a2fe/c4404e92055a461b85f5cf0c06bb8497.jpg, createdBy=06ab5182837, createdName=146fe014m90暂无昵称, createdTime=Sat Jul 24 15:09:02 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026921, encodeId=299710269210c, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Sat Jul 24 14:21:37 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036762, encodeId=9f361036e62ed, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Sat Jul 24 14:21:37 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047402, encodeId=bdc8104e402ce, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Jul 24 14:21:37 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002207, encodeId=2f98100220ee6, content=学到了<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e3a5478833, createdName=ms5000000790714074, createdTime=Sat Jul 24 12:57:38 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002199, encodeId=ef42100219917, content=我想问的是能否替代氯吡格雷。, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c172830082, createdName=18327b53a6m, createdTime=Sat Jul 24 11:52:33 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002193, encodeId=949710021936c, content=又是阿司匹林, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210616/0f0e195fe7b24d569a1f39751df92fe2/ae01b1208252480f9e001617ce565271.jpg, createdBy=91e25526337, createdName=土豆你个马铃薯, createdTime=Sat Jul 24 11:23:00 CST 2021, time=2021-07-24, status=1, ipAttribution=)]
    2021-07-24 ms5000000790714074

    学到了#学习#

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1720403, encodeId=66b21e2040356, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Sun Jun 19 10:21:37 CST 2022, time=2022-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006810, encodeId=4c8a100681095, content=学到了👌, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210121/3066131e88ca4c31a238db2bedac2f10/1d8e8a6a6c4c4256b2b4a24b6723d68a.jpg, createdBy=91092531490, createdName=滚滚兔🐰, createdTime=Tue Aug 10 23:55:38 CST 2021, time=2021-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002363, encodeId=da30100236300, content=非常受用, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210724/725901dc0ed249ebba9d096aacddde3f/a89b874e17434adb82b0c2dff5f374f1.jpg, createdBy=c0225555986, createdName=@gxl, createdTime=Sat Jul 24 19:23:23 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002230, encodeId=77b81002230ff, content=所以现在临床使用上面两个药相对安全吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210923/798b9a11e1834c52b6667d71ec29a2fe/c4404e92055a461b85f5cf0c06bb8497.jpg, createdBy=06ab5182837, createdName=146fe014m90暂无昵称, createdTime=Sat Jul 24 15:09:02 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026921, encodeId=299710269210c, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Sat Jul 24 14:21:37 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036762, encodeId=9f361036e62ed, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Sat Jul 24 14:21:37 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047402, encodeId=bdc8104e402ce, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Jul 24 14:21:37 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002207, encodeId=2f98100220ee6, content=学到了<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e3a5478833, createdName=ms5000000790714074, createdTime=Sat Jul 24 12:57:38 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002199, encodeId=ef42100219917, content=我想问的是能否替代氯吡格雷。, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c172830082, createdName=18327b53a6m, createdTime=Sat Jul 24 11:52:33 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002193, encodeId=949710021936c, content=又是阿司匹林, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210616/0f0e195fe7b24d569a1f39751df92fe2/ae01b1208252480f9e001617ce565271.jpg, createdBy=91e25526337, createdName=土豆你个马铃薯, createdTime=Sat Jul 24 11:23:00 CST 2021, time=2021-07-24, status=1, ipAttribution=)]
    2021-07-24 18327b53a6m

    我想问的是能否替代氯吡格雷。

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1720403, encodeId=66b21e2040356, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Sun Jun 19 10:21:37 CST 2022, time=2022-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006810, encodeId=4c8a100681095, content=学到了👌, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210121/3066131e88ca4c31a238db2bedac2f10/1d8e8a6a6c4c4256b2b4a24b6723d68a.jpg, createdBy=91092531490, createdName=滚滚兔🐰, createdTime=Tue Aug 10 23:55:38 CST 2021, time=2021-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002363, encodeId=da30100236300, content=非常受用, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210724/725901dc0ed249ebba9d096aacddde3f/a89b874e17434adb82b0c2dff5f374f1.jpg, createdBy=c0225555986, createdName=@gxl, createdTime=Sat Jul 24 19:23:23 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002230, encodeId=77b81002230ff, content=所以现在临床使用上面两个药相对安全吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210923/798b9a11e1834c52b6667d71ec29a2fe/c4404e92055a461b85f5cf0c06bb8497.jpg, createdBy=06ab5182837, createdName=146fe014m90暂无昵称, createdTime=Sat Jul 24 15:09:02 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026921, encodeId=299710269210c, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Sat Jul 24 14:21:37 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036762, encodeId=9f361036e62ed, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Sat Jul 24 14:21:37 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047402, encodeId=bdc8104e402ce, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Jul 24 14:21:37 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002207, encodeId=2f98100220ee6, content=学到了<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e3a5478833, createdName=ms5000000790714074, createdTime=Sat Jul 24 12:57:38 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002199, encodeId=ef42100219917, content=我想问的是能否替代氯吡格雷。, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c172830082, createdName=18327b53a6m, createdTime=Sat Jul 24 11:52:33 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002193, encodeId=949710021936c, content=又是阿司匹林, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210616/0f0e195fe7b24d569a1f39751df92fe2/ae01b1208252480f9e001617ce565271.jpg, createdBy=91e25526337, createdName=土豆你个马铃薯, createdTime=Sat Jul 24 11:23:00 CST 2021, time=2021-07-24, status=1, ipAttribution=)]
    2021-07-24 土豆你个马铃薯

    又是阿司匹林

    0

拓展阅读

ESC 2023 重磅研究 |在新一代药物洗脱支架时代,DAPT仍应是PCI的标准策略(STOPDAPT-3试验)

作为DAPT的一部分,在PCI术后1个月内使用阿司匹林可能会对冠状动脉病变起到保护作用,尤其是在ACS患者中,大出血的发生率不会大幅增加。

JAMA Neurology:阿司匹林基础上小中风和TIA患者应该选择替格瑞洛or氯吡格雷?

将阿司匹林与替格瑞洛或氯吡格雷相结合的DAPT优于单用阿司匹林,但在主要结果方面,2种方案之间没有发现统计学上的显著差异。

JAMA NEURO/天坛王拥军团队:CYP2C19功能缺失等位基因的急性中风或TIA患者使用替格瑞洛和阿司匹林的益处和风险

在携带CYP2C19 LOF等位基因的轻微卒中或TIA患者中,使用替格瑞洛和阿司匹林的益处主要出现在第一周,在接下来的2周内会有额外的少量益处。

circulation:依度沙班与双重抗血小板疗法治疗TAVR术后脑血栓没有差异

在成功的TAVR术后没有长期抗凝适应症的患者中,使用依度沙班的瓣膜血栓发生率在数字上低于DAPT,但这并不具有统计学意义。

JAMA子刊:阿司匹林基础上,替格瑞洛vs氯吡格雷DAPT治疗中风的效果无差!

阿司匹林与替格瑞洛或氯吡格雷相结合的DAPT优于单用阿司匹林,但在主要结果方面,2种方案之间没有发现统计学上的显著差异。

BMJ:重磅!冠脉重建后DAPT治疗的核心地位被动摇,P2Y12抑制剂单药治疗或收益更大

评估P2Y12抑制剂单药治疗与双抗血小板治疗(DAPT)的风险和收益,以及这些关联是否因患者的特点而改变。